Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated January 19, 2022, regarding outcome of the Board Meeting and financials for the quarter and nine months ended December 31, 2021, please find enclosed herewith the copy of newspaper publication of the financials in Financial Express (All India Edition) and Vijayavani (Bengaluru Edition) on January 21, 2022.
Earnings Call for Q3FY22 Syngene International Ltd.
Conference Call with Syngene International Ltd. Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: CEO Johnathan Hunt Q3FY22 Quarterly Result Announced for Syngene International Ltd.
Pharmaceuticals company Syngene International declares Q3FY22 result: Syngene reports 10% growth in revenue from operations to Rs. 6,414 Mn and raises full-year guidance The Company reported revenue from operations growth of 10% year-on-year to Rs. 6,414 Mn, delivering 10% growth in profit before tax to Rs. 1,284 Mn. Profit after tax for the quarter was Rs.1,040 Mn, representing year-on-year growth of 2%. Growth in profit after tax was impacted by a lower effective tax rate in the third quarter last year due to a tax reversal and other factors. For the nine months to December 31 2021, the Company delivered growth of 21% in revenue from operations to Rs.18,461 Mn and profit after tax, before exceptional items, was Rs 2,733 Mn, an increase of 12% compared the same period in the previous year. Based on the Company’s performance to date and the anticipated project deliveries in the fourth quarter, the Company updated the full year revenue growth guidance to high teens, from the mid-teen guidance shared at the beginning of the financial year. Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “Syngene’s performance across all divisions has been positive through the year, and we expect a busy fourth quarter. As a result, we have raised our revenue growth guidance for the full year to high teens. A highlight for the quarter was the extension of our long-standing collaboration with Amgen Inc until 2026. Since 2012, Syngene has been partnering with Amgen on research and development to address some of the most serious diseases in the world. We are delighted with our joint commitment to not only extend the term of this partnership but also add a new stateof-the-art dedicated laboratory to accelerate the advancement of Amgen’s R&D; projects. The 5-year renewal of the long-standing contract with Amgen, coming on the heels of the 10- year contract extension signed with BMS last year, confirms the stability of both relationships and provides a clear perspective on the future of our Dedicated Centers.” Result PDF Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and nine months ended December 31, 2021. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to March 31, 2022. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Press Release in respect of results for the quarter and nine months ended December 31, 2021. With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled 'Syngene reports 10% growth in revenue from operations to Rs. 6,414 Mn and raises full-year guidance' Syngene International Ltd - 539268 - Board Meeting Outcome for Outcome Of The Board Meeting
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the following: Financial Results: Un-audited financial results (consolidated and standalone) as per Indian Accounting Standards (Ind-AS) for the quarter and nine months ended December 31, 2021. A copy of the un-audited financial results along with the Limited Review Reports is enclosed herewith. Syngene International Ltd - 539268 - Outcome Of The Board Meeting
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the following: Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation for conference call for Analysts and Investors to be held on Thursday, January 20, 2022. The above-mentioned information will also be available on website of the Company www.syngeneintl.com. Request to kindly take this intimation on record. Syngene International Ltd - 539268 - Shareholding for the Period Ended December 31, 2021
Syngene International Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
